|
How this guide was prepared. Last updated October 2026. It draws on Brandmovers' experience designing B2B channel incentive programs. It also draws on primary sources: the federal Anti-Kickback Statute and its safe harbor regulations, an HHS Office of Inspector General advisory opinion, Department of Justice and CMS materials, and the AdvaMed Code of Ethics, each checked at its source. |
A healthcare distributor incentive program rewards distributor staff for activities that grow a manufacturer's business, such as training, account development and contract milestones. Because the end customers bill federal healthcare programs, it has to be designed so that no reward can be seen as payment for steering those customers toward reimbursable products.
A channel incentive that would raise no questions for building materials or auto dealers becomes a federal compliance matter when the distributor's customer is a hospital, surgery center or physician practice that bills Medicare, Medicaid, TRICARE or another federal healthcare program. The reason is the federal Anti-Kickback Statute (AKS), which makes it a felony to knowingly and willfully offer or pay anything of value to induce referrals of items or services paid for by federal healthcare programs. Distributor staff often work alongside the clinicians who choose products, so a reward tied to the wrong behavior can look like a kickback. This guide covers the rules that apply, what recent guidance changes, a design framework for compliant programs, how to measure them, and when an incentive program is the wrong tool.
|
The Anti-Kickback Statute applies because it covers anything of value, paid directly or indirectly, where one purpose is to induce referrals of items paid for by federal healthcare programs, and distributor rewards can travel that path.
Under 42 U.S.C. 1320a-7b(b), knowingly and willfully offering or paying remuneration to induce such referrals is a felony, punishable by a fine of up to $100,000, up to 10 years in prison, or both. Three features matter for incentive design:
Distributor programs sit in the risk zone because the reward flows to people who may influence which products a hospital or practice buys and bills to federal healthcare programs. The guide to incentive compliance in regulated industries covers the wider picture.
The safe harbors that matter most are personal services and management contracts, employees, discounts and group purchasing organizations, and each protects only arrangements that meet every condition.
Safe harbors are set out in 42 CFR 1001.952. Meeting one is voluntary; an arrangement that does not fit is judged on its facts rather than automatically unlawful.
Recent guidance reinforces that an arrangement must deliver real commercial value, and one appeals court narrowed what counts as a referral for marketing services; neither makes volume-linked rewards to distributor staff safe.
OIG Advisory Opinion 25-08. Issued on July 1 and posted on July 7, 2025, this unfavorable opinion reviewed a device maker's proposal to pay a billing-software vendor about $395 a year per sales representative, around $1.2 million a year in total, to use a portal that some hospital, health system and surgery center customers requested or required. The company certified that the portal was redundant to its own accounts-receivable processes and so could not certify that the fees were commercially reasonable; its only reason to pay was to keep selling to customers that used the vendor. OIG concluded the arrangement could generate prohibited remuneration and noted "anti-competitive risks and risks of inappropriate steering." The lesson for incentive design: a payment that buys access to customers rather than a service the payer needs is hard to defend, however it is structured.
United States v. Sorensen. On April 14, 2025, the Court of Appeals for the Seventh Circuit reversed the AKS conviction of a medical equipment distributor's owner who had paid advertising and marketing firms, with compensation based on lead generation, to generate orders for braces (No. 24-1557). As summarized by Morgan Lewis, the court held that payments to marketers who lacked "fluid, informal power and influence over health care decisions" were not payments for referrals, noting that about 80% of physicians who received prefilled order forms returned or ignored them. The decision binds only federal courts in Illinois, Indiana and Wisconsin, and it concerns marketing services. A distributor representative who works with the clinicians choosing products, and is rewarded on the sales that follow, is in a different position. Morgan Lewis also notes that the government charged Sorensen under one prong of the statute and that another prong prohibits "the arranging for and/or recommendation of specific goods and services in exchange for remuneration."
The Sunshine Act applies when manufacturer-funded value reaches a covered clinician or teaching hospital, including indirectly through a distributor when the manufacturer directs or causes the payment, because manufacturers must report those transfers to CMS through Open Payments.
Open Payments covered recipients are physicians, advanced practice providers such as physician assistants and nurse practitioners, and teaching hospitals. If a manufacturer requires, instructs, directs or otherwise causes a distributor to pass value to any of them, for example through events, meals or rewards, the manufacturer generally must report it as an indirect payment (42 CFR 403.902), unless it is unaware of the recipient's identity (42 CFR 403.904). A distributor under common ownership with a manufacturer can itself be an applicable manufacturer.
The Medtronic settlement shows the combined risk. In October 2020, the Department of Justice announced that Medtronic USA agreed to pay $8.1 million to resolve allegations that it paid for social events at a restaurant owned by a South Dakota neurosurgeon, more than one hundred over nine years, to induce him to use its SynchroMed II implantable infusion pumps, plus $1.11 million to resolve allegations that it underreported those payments to CMS under Open Payments. DOJ noted that the claims were "allegations only, and there has been no determination of liability."
State laws add limits that apply regardless of who pays for care. Vermont makes it unlawful for a manufacturer of a prescribed product or a wholesale distributor of medical devices, or their agents, to give gifts to health care providers (18 V.S.A. 4631a). Minnesota bars manufacturers and wholesale drug distributors, or their agents, from giving practitioners gifts of value, excluding items worth no more than $50 combined in a calendar year (Minn. Stat. 151.461).
The AdvaMed Code of Ethics expects medical technology companies to extend its standards to the distributors and dealers that sell on their behalf, which makes it a practical baseline for distributor programs in the device sector.
The AdvaMed Code (revised and restated edition effective November 1, 2025, which added a section on data-driven technologies and supersedes the 2020 edition) says a company adopting it "is required to communicate the Code's provisions to its employees, agents, dealers, and distributors, with the expectation that they will adhere to the Code." Its FAQs say the Code is intended to apply to dealers, distributors and resellers, including sub-distributors, that provide sales and marketing support and interact with US health care professionals on the company's behalf. Three provisions shape reward design:
Design a compliant program around four principles: reward commercial activities, document fair market value, limit cash-like rewards for anyone near clinical decisions, and build governance before launch.
Choose behaviors that grow the business without rewarding clinical product selection. Reasonable candidates include new account identification and qualification, demo scheduling, completion of product and compliance training, contract execution or renewal, and documented introduction of a product category to a new customer. Treat with caution, or exclude: rewards on total revenue from products used mainly in federally reimbursed procedures, market share against a named competitor, and anything tied to a product choice for a specific patient. This follows the safe harbor standard that compensation not take into account the volume or value of referrals or business otherwise generated. Milestones such as contract execution still generate business, so they carry less risk than revenue-based rewards but are not risk-free; check them against the statute and safe harbors.
Set a per-participant annual cap before launch and record why it is reasonable for the commercial activities required, independent of any referrals. Keep rewards fixed per milestone rather than scaling with revenue, because a reward that rises in step with sales starts to look like a referral fee. As an illustration only, a top tier might carry a documented annual ceiling; the figure should come from each program's own analysis, not a benchmark.
Cash, checks, bank transfers and gift cards usable like cash are the hardest rewards to distinguish from a payment. For participants with any clinical contact, favor a points catalog of merchandise and personal experiences with item and annual value limits, plus recognition such as achievement awards. Non-cash rewards are still remuneration under the statute; their advantage is that they are easier to value, cap and track. Exclude entertainment for clinical contacts and anything that passes value to a covered recipient without Open Payments tracking. Rewards to people who are not the sponsor's employees are generally taxable income to them, and the IRS form depends on what the reward is for: under the IRS instructions for Forms 1099-MISC and 1099-NEC, awards for services performed by nonemployees, such as an award for the top commission salesperson, go on Form 1099-NEC, while prizes and awards not for services go on Form 1099-MISC. Both apply at $2,000 for tax years beginning after 2025, a threshold that may be adjusted for inflation beginning in 2027, so plan reporting with the tax team.
This is general information, not legal advice.
Compliance works as a design input, not a sign-off after the program is built. OIG's General Compliance Program Guidance (2023) sets out the compliance program elements OIG expects. Before launch, check the structure, eligibility and catalog against the statute and safe harbors; document fair market value; set up tracking of each participant's rewards against the cap; and decide how Open Payments reporting will work for any value that could reach covered recipients. Whatever the platform, including BENGAGED™, Brandmovers' B2B channel incentives platform, write eligibility, caps and excluded rewards into the program rules so the system enforces what was approved. The channel incentive fraud guide covers the audit controls that support this.
|
Program element |
Lower-risk design |
Higher-risk design |
Key distinction |
|---|---|---|---|
|
Rewarded behaviors |
Account development, training, demos, contract milestones with defined completion criteria (checked against the safe harbors) |
Revenue from mainly reimbursed procedures; share against a named competitor; clinical adoption rates |
Commercial activity vs. clinical product selection |
|
Reward type |
Non-cash catalog with documented item values; personal experiences; recognition |
Cash; gift cards usable like cash; entertainment for clinical contacts; untracked awards |
Non-cash with a documented cap vs. cash-like value |
|
Eligibility |
Staff in commercial roles such as account management, logistics and sales operations |
Anyone who hits a revenue threshold, regardless of clinical contact |
Role-based vs. revenue-based eligibility |
|
Value structure |
Fixed values per milestone; annual cap per participant |
Values that scale with reimbursable sales; no cap |
Fixed milestone vs. percentage-like structure |
|
Contact with clinicians |
Bona fide education, independently managed, with Open Payments tracking |
Manufacturer-funded entertainment or value passed to clinicians without reporting |
Education with reporting vs. untracked value |
|
Compliance process |
Reviewed against the statute before launch; ongoing monitoring of caps |
Reviewed after launch or never; no monitoring |
Design input vs. afterthought |
Eligibility should depend on each role's distance from clinical product decisions, because staff who influence which products clinicians choose carry most of the risk.
For each role you plan to include, you should be able to answer yes to three questions:
If any answer is no, decide whether the role can take part and on what terms before it is included.
Device programs raise particular risk because device representatives often work in operating rooms and procedure suites alongside the clinicians who choose products.
A device representative present during procedures and rewarded on procedure volume is close to the clinical decision, so eligibility, reward type and Open Payments tracking need the most care. Pharmaceutical wholesalers and specialty distributors are usually further from prescribing, handling supply, stocking and logistics, but that does not remove the risk: rewarding pharmacy or distributor staff for switching patients or prescribers to a product needs careful review. The pharmaceutical channel loyalty guide covers pharma distribution programs in more depth.
Measure a compliant program on two tracks: whether it changes the commercial behaviors it rewards, and whether its compliance controls hold.
The B2B channel loyalty guide covers commercial measurement for channel programs generally.
A channel incentive program is the wrong tool when the behavior you most want to reward is clinical adoption itself, or when you cannot document fair market value for the rewards.
Healthcare channel incentives can work, but every design choice is also a compliance choice: which behaviors earn rewards, who can take part, what the rewards are and how much they are worth. The programs that hold up are built around commercial activities, documented fair market value, role-based eligibility and governance set before launch. Recent guidance cuts both ways: OIG rejected payments that bought access to customers, while one appeals court narrowed what counts as a referral for marketing firms. Neither protects volume-linked rewards to staff near clinical decisions. If an OIG investigator asked why each reward in your program exists, could you answer from your own documentation?
|
Designing a healthcare channel incentive program? Brandmovers designs B2B channel incentive programs and runs them on BENGAGED, with eligibility, caps and catalog rules set with your compliance counsel before launch. Request a demo to talk it through with the Brandmovers team. |